- Trials with a EudraCT protocol (98)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (38)
98 result(s) found for: Ewing Sarcoma.
Displaying page 2 of 5.
| EudraCT Number: 2007-006719-21 | Sponsor Protocol Number: IMCL CP13-0707 | Start Date*: 2008-08-07 | ||||||||||||||||
| Sponsor Name:ImClone LLC | ||||||||||||||||||
| Full Title: A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET | ||||||||||||||||||
| Medical condition: Previously-treated, advanced or metastatic soft tissue and Ewing’s sarcoma/peripheral primitive neuroectodermal tumor (PNET) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) ES (Completed) DE (Completed) NL (Completed) FR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-011454-17 | Sponsor Protocol Number: EPOC-MS-001 | Start Date*: 2010-02-22 |
| Sponsor Name:Universitätsklinikum Münster | ||
| Full Title: Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia | ||
| Medical condition: Acute lymphoblastic leukaemia Ewing sarcoma Neuroblastoma Soft tissue sarcoma Wilms tumours | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) FR (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002931-27 | Sponsor Protocol Number: I3Y-MC-JPCS | Start Date*: 2020-10-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Rela... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Trial now transitioned) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-003658-13 | Sponsor Protocol Number: EWING2008 | Start Date*: 2009-03-19 | ||||||||||||||||||||||||||
| Sponsor Name:Universitaetsklinikum Muenster | ||||||||||||||||||||||||||||
| Full Title: EWING 2008 | ||||||||||||||||||||||||||||
| Medical condition: Ewing sarcoma Malignant peripheral neuroectodermal tumour Askin tumour Atypical Ewing sarcoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) BE (Completed) NL (Completed) SE (Completed) HU (Completed) FI (Completed) LT (Completed) PL (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2013-003910-42 | Sponsor Protocol Number: UC-0150/1309_SARCOME_12 | Start Date*: 2014-05-06 | |||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||
| Full Title: A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas. | |||||||||||||||||||||||
| Medical condition: Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-005341-38 | Sponsor Protocol Number: P04720 | Start Date*: 2008-06-09 |
| Sponsor Name:Schering Plough Research Institute | ||
| Full Title: A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing’s Sarcoma That Has Relapsed After Standard Systemic Therapy. | ||
| Medical condition: Relapsed resectable and unresectable Osteosarcoma, Ewing Sarcoma. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) FR (Completed) ES (Completed) SE (Prematurely Ended) NO (Prematurely Ended) NL (Completed) IT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-004742-18 | Sponsor Protocol Number: XM22-07 | Start Date*: 2012-04-04 |
| Sponsor Name:Merckle GmbH, a member of the ratiopharm group, a subsidiary of Teva Pharmaceutical Industries Ltd. Germany | ||
| Full Title: Multicenter, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children wit... | ||
| Medical condition: Children with Ewing Family of Tumors or Rhabdomyosarcoma receiving cytotoxic Chemotherapy for malignancy inducing neutropenia | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-004697-41 | Sponsor Protocol Number: GO29664 | Start Date*: 2015-08-19 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Pediatric solid tumors for which prior treatment has proven to be ineffective (i.e., relapsed or refractory) or intolerable | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) DE (Completed) IE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-003602-41 | Sponsor Protocol Number: 2020-012-GLOB2 | Start Date*: 2022-11-15 |
| Sponsor Name:HUTCHMED Limited | ||
| Full Title: AN OPEN-LABEL, MULTICENTER PHASE 1/2 STUDY OF SURUFATINIB IN COMBINATION WITH GEMCITABINE IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | ||
| Medical condition: recurrent or refractory solid tumors or lymphoma (not central nervous system) who have a known or expected dysfunction of vascular endothelial growth factor receptor-1, -2, and -3; fibroblast growt... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004153-93 | Sponsor Protocol Number: iEuroEwing | Start Date*: 2022-06-17 |
| Sponsor Name:German Paediatric Oncology Group | ||
| Full Title: INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA | ||
| Medical condition: Ewing Sarcoma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002464-14 | Sponsor Protocol Number: GEIS-39 | Start Date*: 2017-03-02 |
| Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
| Full Title: Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma | ||
| Medical condition: Cohort 1: Subjects with desmoid tumor Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-002874-10 | Sponsor Protocol Number: 2022-3545 | Start Date*: 2022-12-16 |
| Sponsor Name:Gustave Roussy | ||
| Full Title: Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma | ||
| Medical condition: Newly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcoma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-005294-60 | Sponsor Protocol Number: CRAD001C24114 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | |||||||||||||
| Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003239-38 | Sponsor Protocol Number: PH-L19TNFDOX2-03/16 | Start Date*: 2017-07-28 | ||||||||||||||||
| Sponsor Name:Philogen S.p.A. | ||||||||||||||||||
| Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien... | ||||||||||||||||||
| Medical condition: Unresectable or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-005674-11 | Sponsor Protocol Number: ADVL1412 | Start Date*: 2015-04-08 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:National Cancer Institute | ||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB | ||||||||||||||||||||||||||||||||||||||
| Medical condition: •Childhood Solid Neoplasm •Recurrent Childhood Rhabdomyosarcoma •Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor •Recurrent Neuroblastoma •Recurrent Osteosarcoma •Recurrent ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-000096-32 | Sponsor Protocol Number: METRO-PD1-1708 | Start Date*: 2018-11-15 | ||||||||||||||||||||||||||
| Sponsor Name:Centre Oscar Lambret | ||||||||||||||||||||||||||||
| Full Title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma | ||||||||||||||||||||||||||||
| Medical condition: Progressive or refractory : • high grade glioma • neuroblastoma • other cerebral tumors • lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) BE (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-002366-13 | Sponsor Protocol Number: IB2020-02 | Start Date*: 2021-12-20 | |||||||||||
| Sponsor Name:Institut Bergonié | |||||||||||||
| Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas | |||||||||||||
| Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001263-20 | Sponsor Protocol Number: D-FR-01087-001 | Start Date*: 2018-12-18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Ipsen Pharma SAS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: An International Multicentre, Open-Label First in Human Phase I/II study to evaluate the safety, tolerability, biodistribution and antitumour activity of 177Lu-3BP-227 for the treatment of subjects... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with unresecable, metastatic or locally advanced cancers expressing Neurotensin Receptor 1 (NTSR1). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) NL (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-001108-11 | Sponsor Protocol Number: EORTC protocol 62033 | Start Date*: 2004-11-08 | |||||||||||
| Sponsor Name:European Organisation for the Research and Treatment of Cancer | |||||||||||||
| Full Title: A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-bas... | |||||||||||||
| Medical condition: Soft Tissue Sarcoma (STS) is a rare group of heterogeneous mesenchymal cancers originating from connective tissue. There are multiple histological subtypes of STS. At present all these subtypes are... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002584-41 | Sponsor Protocol Number: CEPOETA-2015-01 | Start Date*: 2016-10-24 |
| Sponsor Name:Masarykova univerzita | ||
| Full Title: RECURENT NEUROBLASTOMA AND EWING´S SARCOMA: TREOSULPHAN BASED HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBSC SUPPORT | ||
| Medical condition: Ewing's sarcoma, neuroblastoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
